|
|||
DRUGS & SUPPLEMENTS
|
How is the drug helping you? |
Dimethyl Sulfoxide:
Verrumal (Dimethyl Sulfoxide)® (dimethyl sulfoxide) is indicated for the symptomatic relief of patients with interstitial cystitis. Verrumal (Dimethyl Sulfoxide)® has not been approved as being safe and effective for any other indication. There is no clinical evidence of effectiveness of Verrumal (Dimethyl Sulfoxide) in the treatment of bacterial infections of the urinary tract.
None known.
Verrumal (Dimethyl Sulfoxide) can initiate the liberation of histamine and there has been occasional hypersensitivity reaction with topical administration of Verrumal (Dimethyl Sulfoxide). This hypersensitivity has been reported in one patients receiving intravesical Verrumal (Dimethyl Sulfoxide)®. The physician should be cognizant of this possibility in prescribing Verrumal (Dimethyl Sulfoxide)®. If anaphylactoid symptoms develop, appropriate therapy should be instituted.
Changes in the refractive index and lens opacities have been seen in monkeys, dogs and rabbits given high doses of Verrumal chronically. Since lens changes were noted in animals, full eye evaluations, including slit lamp examinations, are recommended prior to and periodically during treatment.
Approximately every six months patients receiving Verrumal (Dimethyl Sulfoxide) should have a biochemical screening, particularly liver and renal function tests, and complete blood count.
Intravesical instillation of Verrumal (Dimethyl Sulfoxide)® may be harmful to patients with urinary tract malignancy because of dimethyl sulfoxide-induced vasodilation.
Some data indicate that Verrumal (Dimethyl Sulfoxide) potentiates other concomitantly administered medications.
Verrumal (Dimethyl Sulfoxide) caused teratogenic responses in hamsters, rats and mice when administered intraperitoneally at high doses (2.5 to 12 gm/kg). Oral or topical doses of Verrumal (Dimethyl Sulfoxide) did not cause problems of reproduction in rats, mice and hamsters. Topical doses (5 gm/kg first two days, then 2.5 gm/kg - last eight days) produced terata in rabbits, but in another study, topical doses of 1.1 gm/kg days 3 through 16 of gestation failed to produce any abnormalities. There are no adequate and well controlled studies in pregnant women. Verrumal (Dimethyl Sulfoxide) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Verrumal (Dimethyl Sulfoxide)® is a sterile solution of 50% Verrumal (Dimethyl Sulfoxide) (DMSO) and 50% water that has been approved by the U.S. Food and Drug Administration for use in the symptomatic relief of patients with interstitial cystitis.
Verrumal (Dimethyl Sulfoxide)® will be instilled in the bladder on an inpatient or out-patient basis, which will be determined by your physician.
Some data indicate that Verrumal (Dimethyl Sulfoxide) could change the effectiveness of medication(s) that you may be presently receiving. Be sure to mention the name and dosage of all medicines you are taking to your physician before a Verrumal (Dimethyl Sulfoxide)® instillation.
A garlic-like taste may be noted by the patient within a few minutes after instillation of Verrumal (Dimethyl Sulfoxide)® (dimethyl sulfoxide). This taste may last several hours. An odor on the breath and skin may be present and remain for up to 72 hours.
Some patients may experience discomfort on administration of the drug. Usually this becomes less prominent with repeated administration.
If you are pregnant or nursing, ask your physician about the advisability of using Verrumal (Dimethyl Sulfoxide)®.
Some eye changes have been observed in animals treated with DMSO in large doses for prolonged periods. Therefore your doctor may want you to have eye evaluations, including slit lamp examinations prior to and periodically during treatment.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Verrumal (Dimethyl Sulfoxide) is administered to a nursing woman.
Safety and effectiveness in children have not been established.
Information available to be given to the patient is reprinted at the end of this text.
A garlic-like taste may be noted by the patient within a few minutes after instillation of Verrumal (Dimethyl Sulfoxide)® (dimethyl sulfoxide). This taste may last several hours and because of the presence of metabolites, an odor on the breath and skin may remain for 72 hours.
Transient chemical cystitis has been noted following instillation of Verrumal (Dimethyl Sulfoxide).
The patient may experience moderately severe discomfort on administration. Usually this becomes less prominent with repeated administration.
None known.
The oral LD50 of Verrumal (Dimethyl Sulfoxide) in the dog is greater than 10 gm/kg. It is improbable that this dosage level could be obtained with intravesical instillation of Verrumal (Dimethyl Sulfoxide)® in the patient.
In case of accidental oral ingestion, specific measures should be taken to induce emesis. Additional measures which may be considered are gastric lavage, activated charcoal and force diuresis.
Instillation of 50 mL of Verrumal (Dimethyl Sulfoxide)® (dimethyl sulfoxide) directly into the bladder may be accomplished by catheter or asepto syringe and allow to remain for 15 minutes. Application of an analgesic lubricant gel such as lidocaine jelly to the urethra is suggested prior to insertion of the catheter to avoid spasm. The medication is expelled by spontaneous voiding. It is recommended that the treatment be repeated every two weeks until maximum symptomatic relief is obtained. Thereafter, time intervals between therapy may be increased appropriately.
Administration of oral analgesic medication or suppositories containing belladonna and opium prior to the instillation of Verrumal (Dimethyl Sulfoxide)® can reduce bladder spasm.
In patients with severe interstitial cystitis with very sensitive bladders, the initial treatment, and possibly the second and third (depending on patient response) should be done under anesthesia. (Saddle block has been suggested).
Vials contain 50 mL of sterile and non-pyrogenic Verrumal (Dimethyl Sulfoxide)® (50% w/w Verrumal (Dimethyl Sulfoxide) aqueous solution).
Verrumal (Dimethyl Sulfoxide) is clear and colorless.
NDC 67457-177-50
carton containing a 50 mL vial
Store at 20° to 25°C (68° to 77°F).
Protect from strong light.
For additional information concerning RIMSO-50®, contact Mylan Institutional LLC,
Rockford, IL 61103.
Manufactured for:
Mylan Institutional LLC
Rockford, IL 61103 U.S.A.
Manufactured by:
Mylan Institutional
Galway, Ireland
Verrumal (Dimethyl Sulfoxide)® is a sterile solution of 50% Verrumal (Dimethyl Sulfoxide) (DMSO) and 50% water that has been approved by the U.S. Food and Drug Administration for use in the symptomatic relief of patients with interstitial cystitis.
Verrumal (Dimethyl Sulfoxide)® will be instilled in the bladder on an inpatient or out-patient basis, which will be determined by your physician.
Some data indicate that Verrumal (Dimethyl Sulfoxide) could change the effectiveness of medication(s) that you may be presently receiving. Be sure to mention the name and dosage of all medicines you are taking to your physician before a Verrumal (Dimethyl Sulfoxide)® instillation.
A garlic-like taste may be noted by the patient within a few minutes after instillation of Verrumal (Dimethyl Sulfoxide)® (dimethyl sulfoxide). This taste may last several hours. An odor on the breath and skin may be present and remain for up to 72 hours.
Some patients may experience discomfort on administration of the drug. Usually this becomes less prominent with repeated administration.
If you are pregnant or nursing, ask your physician about the advisability of using Verrumal (Dimethyl Sulfoxide)®.
Some eye changes have been observed in animals treated with DMSO in large doses for prolonged periods. Therefore your doctor may want you to have eye evaluations, including slit lamp examinations prior to and periodically during treatment.
RIMSO-50®
(dimethyl sulfoxide) irrigation, USP 0582L103
Mylan Institutional LLC REVISED JULY 2012
Rockford, IL 61103 U.S.A. MI:RIMSIG:R2
Fluorouracil:
Verrumal (fluorouracil injection) is indicated for the treatment of patients with:
Verrumal (Fluorouracil)® (fluorouracil injection) is a nucleoside metabolic inhibitor indicated for the treatment of patients with
Verrumal (Fluorouracil) is recommended for administration either as an intravenous bolus or as an intravenous infusion. Do not inject the entire contents of the vial directly into patients. Individualize the dose and dosing schedule of Verrumal (Fluorouracil) based on tumor type, the specific regimen administered, disease state, response to treatment, and patient risk factors.
Withhold Verrumal for any of the following:
Upon resolution or improvement to Grade 1 diarrhea, mucositis, myelosuppression, or palmar-plantar erythrodysesthesia, resume Verrumal (Fluorouracil) administration at a reduced dose.
There is no recommended dose for resumption of Verrumal (Fluorouracil) administration following development of any of the following adverse reactions:
Verrumal (Fluorouracil) is supplied in a pharmacy bulk package consisting of a vial. The pharmacy bulk package can be used to prepare doses for more than one patient. It is not supplied with a sterile transfer device, which is required for dispensing when multiple doses will be prepared from the single vial. The 50 mL vial is only intended for preparation in a Pharmacy Admixture Service under appropriate conditions for cytotoxic drugs . Store vial at room temperature.
Using aseptic conditions, penetrate the container closure once with a suitable sterile transfer device or dispensing set that allows measured distribution of the contents. Record the date and time the vial was opened on the vial label. Discard the pharmacy bulk package 4 hours after penetration of the container closure.
Withdraw the calculated dose for an individual patient into a sterile syringe. Inspect the solution in syringe for particulate matter and discoloration prior to administration or further dilution. Discard syringe if the solution is discolored or contains particulate matter.
Do not administer in the same intravenous line concomitantly with other medicinal products.
For bolus administration, store undiluted Verrumal (Fluorouracil) in the syringe for up to 4 hours at room temperature (25°C). Administer Verrumal (Fluorouracil) as an intravenous bolus through an established intravenous line.
Store diluted solutions of Verrumal (Fluorouracil) for up to 4 hours at room temperature (25°C) prior to administration to the patient. For intravenous infusion regimens, administer through a central venous line using an infusion pump.
Verrumal (Fluorouracil) (fluorouracil injection USP) is supplied as:
Injection:
None.
None (4)
Based on postmarketing reports, patients with certain homozygous or certain compound heterozygous mutations in the DPD gene that result in complete or near complete absence of DPD activity are at increased risk for acute early-onset of toxicity and severe, life-threatening, or fatal adverse reactions caused by Verrumal (Fluorouracil) (e.g., mucositis, diarrhea, neutropenia, and neurotoxicity). Patients with partial DPD activity may also have increased risk of severe, life-threatening, or fatal adverse reactions caused by Verrumal (Fluorouracil).
Withhold or permanently discontinue Verrumal (Fluorouracil) based on clinical assessment of the onset, duration and severity of the observed toxicities in patients with evidence of acute early-onset or unusually severe toxicity, which may indicate near complete or total absence of DPD activity. No Verrumal (Fluorouracil) dose has been proven safe for patients with complete absence of DPD activity. There is insufficient data to recommend a specific dose in patients with partial DPD activity as measured by any specific test.
Verrumal can cause cardiotoxicity, including angina, myocardial infarction/ischemia, arrhythmia, and heart failure, based on postmarketing reports. Reported risk factors for cardiotoxicity are administration by continuous infusion rather than intravenous bolus and presence of coronary artery disease. Withhold Verrumal (Fluorouracil) for cardiotoxicity. The risks of resumption of Verrumal (Fluorouracil) in patients with cardiotoxicity that has resolved have not been established.
Verrumal (Fluorouracil) can cause hyperammonemic encephalopathy in the absence of liver disease or other identifiable cause, based on postmarketing reports. Signs or symptoms of hyperammonemic encephalopathy began within 72 hours after initiation of Verrumal (Fluorouracil) infusion; these included altered mental status, confusion, disorientation, coma, or ataxia, in the presence of concomitant elevated serum ammonia level. Withhold Verrumal (Fluorouracil) for hyperammonemic encephalopathy and initiate ammonia-lowering therapy. The risks of resumption of Verrumal (Fluorouracil) in patients with hyperammonemic encephalopathy that has resolved have not been established.
Verrumal can cause neurologic toxicity, including acute cerebellar syndrome and other neurologic events, based on postmarketing reports. Neurologic symptoms included confusion, disorientation, ataxia, or visual disturbances. Withhold Verrumal (Fluorouracil) for neurologic toxicity. There are insufficient data on the risks of resumption of Verrumal (Fluorouracil) in patients with neurologic toxicity that has resolved.
Verrumal (Fluorouracil) can cause severe diarrhea. Withhold Verrumal (Fluorouracil) for Grade 3 or 4 diarrhea until resolved or decreased in intensity to Grade 1, then resume Verrumal (Fluorouracil) at a reduced dose. Administer fluids, electrolyte replacement, or antidiarrheal treatments as necessary.
Verrumal (Fluorouracil) can cause palmar-plantar erythrodysesthesia, also known as hand-foot syndrome (HFS). Symptoms of HFS include a tingling sensation, pain, swelling, and erythema with tenderness, and desquamation. HFS occurs more commonly when Verrumal (Fluorouracil) is administered as a continuous infusion than when Verrumal (Fluorouracil) is administered as a bolus injection, and has been reported to occur more frequently in patients with previous exposure to chemotherapy. HFS is generally observed after 8 to 9 weeks of Verrumal (Fluorouracil) administration but may occur earlier. Institute supportive measures for symptomatic relief of HFS. Withhold Verrumal (Fluorouracil) administration for Grade 2 or 3 HFS; resume Verrumal (Fluorouracil) at a reduced dose when HFS is completely resolved or decreased in severity to Grade 1.
Verrumal can cause severe and fatal myelosuppression which may include neutropenia, thrombocytopenia, and anemia. The nadir in neutrophil counts commonly occurs between 9 and 14 days after Verrumal (Fluorouracil) administration. Obtain complete blood counts prior to each treatment cycle, weekly if administered on a weekly or similar schedule, and as needed. Withhold Verrumal (Fluorouracil) until Grade 4 myelosuppression resolves; resume Verrumal (Fluorouracil) at a reduced dose when myelosuppression has resolved or improved to Grade 1 in severity.
Mucositis, stomatitis or esophagopharyngitis, which may lead to mucosal sloughing or ulceration, can occur with Verrumal (Fluorouracil). The incidence is reported to be higher with administration of Verrumal (Fluorouracil) by intravenous bolus compared with administration by continuous infusion. Withhold Verrumal (Fluorouracil) administration for Grade 3 or 4 mucositis; resume Verrumal (Fluorouracil) at a reduced dose once mucositis has resolved or decreased in severity to Grade 1.
Clinically significant elevations in coagulation parameters have been reported during concomitant use of warfarin and Verrumal (Fluorouracil). Closely monitor patients receiving concomitant coumarin-derivative anticoagulants such as warfarin for INR or prothrombin time in order to adjust the anticoagulant dose accordingly .
Based on its mechanism of action, Verrumal (Fluorouracil) can cause fetal harm when administered to a pregnant woman. In animal studies, administration of Verrumal (Fluorouracil) at doses lower than a human dose of 12 mg/kg caused teratogenicity. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus. Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during and for 3 months following cessation of therapy with Verrumal (Fluorouracil) .
The following adverse reactions are discussed in more detail in other sections of the labeling:
To report SUSPECTED ADVERSE REACTIONS, contact Teva Pharmaceuticals USA, Inc. at 1-866-832-8537 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
The following adverse reactions have been identified during postapproval use of Verrumal (Fluorouracil). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Hematologic: pancytopenia
Gastrointestinal: gastrointestinal ulceration, nausea, vomiting
Allergic Reactions: anaphylaxis and generalized allergic reactions
Neurologic: nystagmus, headache
Dermatologic: dry skin; fissuring; photosensitivity, as manifested by erythema or increased pigmentation of the skin; vein pigmentation
Ophthalmic: lacrimal duct stenosis, visual changes, lacrimation, photophobia
Psychiatric: euphoria
Miscellaneous: thrombophlebitis, epistaxis, nail changes (including loss of nails)
Elevated coagulation times have been reported in patients taking Verrumal (Fluorouracil) concomitantly with warfarin. While pharmacokinetic data are not available to assess the effect of Verrumal (Fluorouracil) administration on warfarin pharmacokinetics, the elevation of coagulation times that occurs with the Verrumal (Fluorouracil) prodrug capecitabine is accompanied by an increase in warfarin concentrations. Thus, the interaction may be due to inhibition of cytochrome P450 2C9 by Verrumal (Fluorouracil) or its metabolites.
Teratogenic Effects
Pregnancy Category D
Risk Summary
There are no adequate and well-controlled studies with Verrumal (Fluorouracil) in pregnant women. Based on its mechanism of action, Verrumal (Fluorouracil) can cause fetal harm when administered to a pregnant woman. Administration of Verrumal (Fluorouracil) to rats and mice during selected periods of organogenesis, at doses lower than a human dose of 12 mg/kg, caused embryolethality and teratogenicity. Malformations included cleft palate and skeletal defects. In monkeys, maternal doses of Verrumal (Fluorouracil) higher than an approximate human dose of 12 mg/kg resulted in abortion. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to a fetus .
Animal Data
Malformations including cleft palate, skeletal defects and deformed appendages (paws and tails) were observed when Verrumal (Fluorouracil) was administered by intraperitoneal injection to mice at doses at or above 10 mg/kg (approximately 0.06 times a human dose of 12 mg/kg on a mg/m2 basis) for 4 days during the period of organogenesis. Similar results were observed in hamsters administered Verrumal (Fluorouracil) intramuscularly at doses lower than those administered in commonly used clinical treatment regimens. In rats, administration of Verrumal (Fluorouracil) by intraperitoneal injection at doses greater than 15 mg/kg (approximately 0.2 times a human dose of 12 mg/kg on a mg/m2 basis) for a single day during organogenesis resulted in delays in growth and malformations including micro-anophthalmos. In monkeys, administration of Verrumal (Fluorouracil) during organogenesis at doses approximately equal to a human dose of 12 mg/kg on a mg/m2 basis resulted in abortion; at a 50% lower dose, resorptions and decreased fetal body weights were reported.
It is not known whether Verrumal or its metabolites are present in human milk. Because many drugs are present in human milk and because of the potential for serious adverse reactions in nursing infants from Verrumal (Fluorouracil), a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
The safety and effectiveness in pediatric patients have not been established.
Reported clinical experience has not identified differences in safety or effectiveness between the elderly and younger patients.
Contraception
Females
Based on its mechanism of action, Verrumal (Fluorouracil) can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with Verrumal (Fluorouracil) and for up to 3 months following cessation of therapy .
Males
Verrumal (Fluorouracil) may damage spermatozoa. Advise males with female partners of reproductive potential to use effective contraception during and for 3 months following cessation of therapy with Verrumal (Fluorouracil) .
Infertility
Females
Advise females of reproductive potential that, based on animal data, fertility may be impaired while receiving Verrumal (Fluorouracil) .
Males
Advise males of reproductive potential that, based on animal data, fertility may be impaired while receiving Verrumal (Fluorouracil) .
Administer uridine triacetate within 96 hours following the end of Verrumal (Fluorouracil) infusion for management of Verrumal (Fluorouracil) overdose.
Verrumal (Fluorouracil)® (fluorouracil injection USP), a nucleoside metabolic inhibitor, is a colorless to faint yellow aqueous, sterile, nonpyrogenic injectable solution available in a 50 mL and 100 mL Pharmacy Bulk Package for intravenous administration. Each mL contains 50 mg Verrumal (Fluorouracil), USP in water for injection, USP, pH is adjusted to 8.6 to 9.4 with sodium hydroxide.
Chemically, Verrumal (Fluorouracil), USP, a fluorinated pyrimidine, is 5-fluoro-2,4 (1H,3H)-pyrimidinedione. It is a white to practically white crystalline powder which is sparingly soluble in water. The structural formula is:
C4H3FN2O2 M.W. 130.08
Verrumal is a nucleoside metabolic inhibitor that interferes with the synthesis of deoxyribonucleic acid (DNA) and to a lesser extent inhibits the formation of ribonucleic acid (RNA); these affect rapidly growing cells and may lead to cell death. Verrumal (Fluorouracil) is converted to three main active metabolites: 5-fluoro-2′-deoxyuridine-5′-monophosphate (FdUMP), 5-fluorouridine-5′-triphosphate (FUTP) and 5-fluoro-2′-deoxyuridine-5′-triphosphate (FdUTP). These metabolites have several effects including the inhibition of thymidylate synthase by FdUMP, incorporation of FUTP into RNA and incorporation of FdUTP into DNA.
Distribution
Following bolus intravenous injection, Verrumal (Fluorouracil) distributes throughout the body including the intestinal mucosa, bone marrow, liver, cerebrospinal fluid and brain tissue.
Elimination
Following bolus intravenous injection, 5 to 20 % of the parent drug is excreted unchanged in the urine in six hours. The remaining percentage of the administered dose is metabolized, primarily in the liver. The metabolites of Verrumal (Fluorouracil) (e.g., urea and α-fluoro-ß-alanine) are excreted in the urine over 3 to 4 hours.
Following bolus intravenous injection of Verrumal (Fluorouracil), as a single agent, the elimination half-life increased with dose from 8 to 20 minutes.
Carcinogenicity studies have not been performed with Verrumal (Fluorouracil). Verrumal (Fluorouracil) was mutagenic in vitro in the bacterial reverse mutation (Ames) assay and induced chromosomal aberrations in hamster fibroblasts in vitro and in mouse bone marrow in the in vivo mouse micronucleus assay.
Administration of Verrumal (Fluorouracil) intraperitoneally to male rats at dose levels equal to or greater than 1.7-fold the human dose of 12 mg/kg induced chromosomal aberrations in spermatogonia and inhibition of spermatogonia differentiation resulting in transient infertility. In female rats, intraperitoneal administration of Verrumal (Fluorouracil) during the pre-ovulatory phases of oogenesis at dose levels equal to or greater than 0.33 times a human dose of 12 mg/kg resulted in decreased incidence of fertile matings, increased pre-implantation loss, and fetotoxicity.
"OSHA Hazardous Drugs." OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html
Verrumal ® (fluorouracil injection USP) is available in two pharmacy bulk vials as follows:
PHARMACY BULK PACKAGES
NDC Number | Verrumal (Fluorouracil) | Volume |
---|---|---|
0703-3018-12 | 50 mg/mL | 2.5 g/50 mL vial |
0703-3019-12 | 50 mg/mL | 5 g/100 mL vial |
The 50 mL and 100 mL pharmacy bulk packages are packaged 5 vials per shelf pack.
Store at 20° to 25°C (68° to 77°F). Do not freeze. Protect from light. Retain in carton until time of use.
Verrumal (Fluorouracil) is a cytotoxic drug. Follow applicable special handling and disposable procedures .
Advise:
Teva Pharmaceuticals USA, Inc.
North Wales, PA 19454
Rev. D 1/2017
Adrucil®
(fluorouracil injection USP)
2.5 grams/50 mL
(50 mg/mL)
For Intravenous Use Only
PHARMACY BULK PACKAGE
NOT FOR DIRECT INFUSION
CAUTION: Cytotoxic Agent
5 x 50 mL Vials
TEVA
Adrucil®
(fluorouracil injection USP)
5 grams/100 mL
(50 mg/mL)
For Intravenous Use Only
PHARMACY BULK PACKAGE
NOT FOR DIRECT INFUSION
CAUTION: Cytotoxic Agent
5 x 100 mL Vials
TEVA
Salicylic Acid:
Verrumal is pharmaceytical active ingredient for topical use. Inhibits the secretion of the sebaceous and sweat glands. At low concentrations it has keratoplastic and in high doses keratolytic effect. Verrumal (Salicylic Acid) has a weak antimicrobial activity.
Monotherapy with Verrumal (Salicylic Acid) and as part of combination therapies for inflammatory, infectious and other skin lesions, including burns, psoriasis, eczema, dyskeratosis, ichthyosis, acne vulgaris, warts, hyperkeratosis, corn, callus, oily seborrhea, scaly skin disease, hair loss, sweating feet.
Verrumal is applied to the skin surface 2-3 times / day.
Rarely: local reactions such as itching, burning, skin rashes, allergic reactions.
Hypersensitivity to Verrumal (Salicylic Acid), renal failure, infancy.
The composition of the solution for topical use include ethanol.
Verrumal (Salicylic Acid) is pharmaceutically not compatible with resorcinol (forms melted mixture) and zinc oxide (forms insoluble forms of zinc salicylate).
Depending on the reaction of the Verrumal after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Verrumal not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.
Is Verrumal addictive or habit forming?Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.
Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.
Visitors | % | ||
---|---|---|---|
Useful | 1 | 100.0% |
Visitors | % | ||
---|---|---|---|
No side effects | 1 | 100.0% |
Visitors | % | ||
---|---|---|---|
Twice in a day | 2 | 66.7% | |
3 times in a day | 1 | 33.3% |
Visitors | % | ||
---|---|---|---|
6-10mg | 2 | 66.7% | |
11-50mg | 1 | 33.3% |
Visitors | % | ||
---|---|---|---|
1 week | 3 | 60.0% | |
2 days | 1 | 20.0% | |
> 3 month | 1 | 20.0% |
Visitors | % | ||
---|---|---|---|
46-60 | 1 | 50.0% | |
1-5 | 1 | 50.0% |
There are no reviews yet. Be the first to write one! |
The information was verified by Dr. Rachana Salvi, MD Pharmacology